Compare Ecopetrol SA (EC) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecopetrol SA vs Novo Nordisk A/S — how do they compare? Ecopetrol SA trades at $16.93 (market cap $34.09B), while Novo Nordisk A/S trades at $38.2 (market cap $168.73B). The key difference: Novo Nordisk A/S is far larger — about 4.9× Ecopetrol SA's market cap, and Novo Nordisk A/S pays the higher dividend (4.7%). Which is the better fit depends on your goals — on Pluang, investors hold Ecopetrol SA for 84 Days and Novo Nordisk A/S for 116 Days on average.
| EC | NVO | |
|---|---|---|
Market Cap | $34.09B | $168.73B |
Volume | 952,204 | 13,531,267 |
Sector | Energy | Health |
52-Week High | $18.26 | $63.98 |
52-Week Low | $8.61 | $35.29 |
Typical Hold Time | 84 Days | 116 Days |
Enterprise Value | $62.65B | $183.05B |
Dividend Yield | 3.91% | 4.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ecopetrol (EC) trades at $16.94, down 0.12% with bearish technical signals. The stock shows attractive valuation metrics including P/E of 7.99 and P/S of 0.91, but faces declining revenue from $159.6B in 2022 to $119.7B in 2025. Recent management changes and board restructuring under Colombia's new government create uncertainty, while the company maintains positive cash flow from operations despite recent earnings misses.
EC presents a value opportunity with discounted multiples but faces operational headwinds. The key investment thesis balances cheap valuation against declining revenue trends and political uncertainty. Risks include continued earnings volatility and government influence, while potential upside exists if new management can stabilize operations and reverse the revenue decline trajectory.
Novo Nordisk (NVO) trades at $38.18, up 1.73% with strong fundamentals including 35.35% net margin and 59.82% ROE. The stock shows mixed technical signals with bullish oscillators but bearish moving averages. Recent earnings consistently beat estimates, with Q2 2026 EPS of $0.96 surpassing the $0.82 expectation. The company maintains robust cash flow generation of $119.1B from operations in 2025.
NVO presents compelling value with a 9.71 P/E ratio and 16.8% upside to the $44.67 consensus target. Key risks include FDA regulatory delays for hemophilia drug denecimig and intensifying competition from Eli Lilly in obesity treatments. The bullish analyst consensus (59% buy ratings) supports the growth outlook despite near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ecopetrol SA
Ecopetrol SA is a vertically integrated oil company with operations in Latin America and the United States Gulf Coast. Based out of Colombia, the company explores, develops, and conducts production activities in various countries. Ecopetrol works as the primary operator or partner in a joint venture, in a host of assets held onshore and offshore. Along with production, the company refines and markets crude oils and byproducts produced from its fields. Crude products are moved by Ecopetrol through a series of pipelines throughout Colombia, along with a network of third-party production centers and facilities.
Read more on EC →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
